Abstract Body

Cross-sectional studies, including our NOVICE study (Neurological Visual and Cognitive performance in treated perinatally HIV-infected [PHIV] children compared to age-, sex-, ethnicity- and socioeconomic status [SES]-matched HIV-uninfected controls), have reported lower white matter (WM) and grey matter (GM) volumes, higher WM hyperintensity (WMH) volume and poorer WM integrity measures in treated PHIV children. It is however unknown whether these differences originated before treatment initiation, or may be progressive over time. This longitudinal study compares the rates of change over time.

We approached all NOVICE participants, to repeat 3T magnetic resonance imaging (MRI) at the Amsterdam University Medical Centers, the Netherlands, after a mean of 4.6±0.3 years. We repeated GM and WM volume, WMH volume and WM integrity measures (total fractional anisotropy [FA], mean diffusivity [MD], radial diffusivity [RD], and axial diffusivity [AD]), obtained by T1-weighted-, FLAIR and DTI MRI, respectively. We compared rates of change between groups using multivariable linear mixed effects models, adjusted for sex and age at first MRI, and we investigated disease- and treatment related factors as determinants of poorer outcomes.­

20 out of 31(65%) PHIV and 20 out of 37(54%) controls completed a second MRI examination. Those who gave consent for follow-up MRI were not statistically different compared to those who did not gave consent in volumetric outcomes and FA at first MRI (all p-values>0.05). Those who completed two MRI examinations had a mean age of 13.0±3.1 years and 17.6±3.1 years at first and second MRI, respectively. PHIV and controls were not statistically different in age, sex, ethnicity, and SES (all p-values>0.05). At p<0.1, WMH volume increased significantly more in PHIV participants (group*time 0.10mL, 95%CI 0.02–0.18, p=0.017) compared to controls (figure 1), which was not associated with disease- and treatment related factors (all p-values>0.05). GM volume decreased significantly less in PHIV (group*time 0.010L, 95% CI -0.001–0.020, p=0.078). We found no statistically different changes over time in WM volume (group*time 0.001, 95%CI -0.006–0.008, p=0.795), nor in WM integrity measures (group*time p-values>0.356).

Results indicate progressive cerebral differences as WMH progress over time in long-term cART-treated PHIV adolescents. Future analyses should further investigate determinants of WMH progression.